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Abstract	
	
Current	Quality	Control	(QC)	practices	for	diagnostic	immunohistochemistry	(IHC)	use	
archived	breast	cancer	specimens	and	breast	cancer	cell	lines	as	control	materials	for	
Estrogen	 Receptor	 (ER)	 and	 Progesterone	 Receptor	 (PR)	 testing	 in	 breast	 cancer.	
However,	 archived	breast	 tumors	 show	 inherent	heterogeneity	within	and	between	
specimens	 and	 cell	 lines	 are	 not	 histologically	 representative	 of	 patient-derived-
tumor	 controls.	 In	 an	 effort	 to	 generate	 standardized	 controls	 for	 ER	 and	 PR	 IHC	
testing,	 I	 hypothesized	 breast	 cancer	 cell	 line-derived	 xenografted	 tumors	 are	
representative	 of	 patient-derived-tumor	 controls	 that	 can	 be	 used	 for	 QC	
purposes.	Well-characterized	breast	cancer	cell	 lines	with	varying	steady-state	 levels	
of	ER	and	PR	expression	–	MCF7,	T47D	and	MDAMB468	–	analyzed	by	 immunoblot	
and	 IHC	 were	 implanted	 in	 immune-deficient	 mice	 to	 generate	 cell	 line-derived	
Xenografted	 (CDX)	 tumors.	 ER	 and	 PR	 expression	 of	 the	 Xenografted	 tumors	 was	
consistent	with	the	derivative	cell	lines.	Three	pathologists	expert	in	breast	biomarker	
reporting	assessed	CDX	 tumors	 for	 reproducibility	 from	different	Mammary	Fat	Pad	
(MFP)	sites	in	the	mice.	The	CDX	tumors	were	indistinguishable	regardless	of	the	MFP	
sites.	 The	 xenografted	 tumors	 from	 the	 three	 cell	 lines	 represented	 the	 range	 of	
biomarker	 expression	 levels	 exhibited	 by	 the	 patient-derived-tumor	 controls.	 These	
results	suggest	the	possible	potential	applications	of	CDX	tumor	as	controls	to	assist	
in	reporting	of	ER	and	PR	test	results.	
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1 Chapter	1	Introduction	
1.1 Breast	cancer	biomarker	testing		
	
In	 clinical	 pathology	 laboratories,	 Immunohistochemistry	 (IHC)	 is	 used	 to	
evaluate	 breast	 cancer	 biomarker	 expression	 levels	 for	 prognostic	 and	 predictive	
testing.	Estrogen	Receptor	(ER)	and	Progesterone	Receptor	(PR)	expression	levels	can	
predict	how	a	patient	will	respond	to	treatment	for	Hormone	Receptor	(HR)	positive	
breast	 cancers1.	 The	 HR	 positive	 cases	 are	 treated	 with	 a	 wide	 range	 of	 drugs	
collectively	called	Selective	Estrogen	Receptor	Modulators	(SERMs)	-	Tamoxifen	is	one	
of	 the	most	widely	 used	 effective	 SERMs2.	Despite	 its	 benefits	 to	 patient	 outcome,	
there	 remain	 ongoing	 issues	 with	 the	 reproducibility	 of	 ER	 and	 PR	 IHC	 test	 results	
between	 local	 and	 central	 laboratories3.	 Approximately	 10	 to	 20	percent	 of	 tumors	
from	 a	 cohort	 of	 1009	 patients	 were	 falsely	 classified	 as	 ER-negative	 in	 a	 recent	
study4.	 Such	 misclassification	 can	 potentially	 change	 the	 treatment	 management	
schemes	for	patients,	prompting	the	issuing	by	a	joint	committee	of	American	Society	
of	Clinical	Oncology	and	College	of	American	Pathologists	(ASCO-CAP)	of	guidelines	on	
ER	 and	PR	 testing	 by	 IHC.	 The	 task	 force	 recommended	exercising	 stringent	 quality	
control	in	every	aspect	of	the	assay	to	minimize	unreliable	test	results2.	
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1.2 Breast	cancer	biomarkers	
The	National	Institute	of	Health	(NIH)	defines	a	biomarker	as,	"a	characteristic	
that	 is	 objectively	 measured	 and	 evaluated	 as	 an	 indicator	 of	 normal	 biological	
processes,	 pathogenic	 processes,	 or	 pharmacologic	 responses	 to	 therapeutic	
intervention5".	 In	 oncology,	 biomarkers	 are	 categorized	 into	 prognostic	 and/or	
predictive	markers.	Prognostic	biomarkers	can	objectively	determine	the	outcome	of	
a	disease	whereas	predictive	biomarkers	 can	 independently	predict	 the	 therapeutic	
outcome	of	a	disease6.	 In	breast	cancer,	hormone	receptors	 that	 include	ER	and	PR	
are	 routinely	 used	 as	 biomarkers.	 Although	 the	 prognosis	 of	 the	 HRs	 is	 debatable,	
they	 have	 shown	 significant	 predictive	 benefit	 on	 patient	 outcome7.	 	 Another	
routinely	 used	 diagnostic	 biomarker	 is	 a	 growth	 factor	 receptor	 called	 human	
epidermal	 growth	 factor	 receptor	 2,	 also	 called	 Her2/neu	 receptor.	 Her2	 receptors	
are	 overexpressed	 in	 approximately	 30	 percent	 of	 invasive	 breast	 cancer	 patients.	
Her2	 receptor	 positive	 breast	 tumors	 have	 poorer	 prognosis	 compared	 to	 breast	
tumors	 without	 Her2	 overexpression.	 However,	 Her2	 receptor	 testing	 followed	 by	
therapeutic	 intervention	 against	 Her2	 positive	 cases	 with	 Trastuzumab	 has	 shown	
significant	 increase	 in	 disease	 free	 survival	 among	 this	 sub	 group	 of	 breast	 cancer	
patients8.	 With	 the	 advancement	 of	 technology	 used	 for	 detecting	 biomolecules,	
more	 promising	 biomarkers	 are	 becoming	 available	 for	 clinical	 use	 for	 better	
management	 of	 the	 disease.	 But	 so	 far,	 the	 challenge	 has	 been	 in	 reproducible	
determination	of	these	biomarkers.		
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1.3 IHC	processing			
IHC	 is	 the	 gold	 standard	 technique	used	 to	 test	 for	 ER	 and	PR	expression	 in	
breast	cancer.	IHC	is	a	complex	technique,	with	multiple	stages	including	pre-analytic,	
analytic	and	post-analytic	 tumor	processing.	Briefly,	 the	pre-analytic	phase	 involves;	
fixing	tumor	specimens	in	a	suitable	preservative,	such	as	10	percent	Neutral	Buffered	
Formalin	 (NBF)	 followed	 by	 paraffin	 embedding.	 The	 Formalin	 Fixed	 Paraffin	
Embedded	 (FFPE)	 tumor	 is	 then	sectioned	and	mounted	on	positively	 charged	glass	
slides.	The	analytic	phase	involves	the	use	of	primary	antibody	designed	specifically	to	
bind	 to	 the	 antigen	 of	 interest	 followed	 by	 a	 series	 of	 detection	 molecules	 that	
catalyzes	 a	 chromogen	 called	 diaminobenzidine	 (DAB)	 and	 stain	 the	 sub-cellular	
regions	brown,	where	the	proteins	of	 interest	are	 localized.	The	post-analytic	phase	
involves	interpretation	and	reporting	of	the	stained	tumor	sections	by	pathologists.		
The	 ASCO-CAP	 guidelines	 for	 HR	 testing	 provide	 insights	 on	 the	 variables	
associated	with	 these	 three	 stages	 of	 IHC	 processing	 that	may	 adversely	 affect	 IHC	
reporting2.	 Hormone	 receptors	 are	 susceptible	 to	 variables	 associated	 with	 pre-
analytic	 phase9.	 It	 is	 recommended	 to	 fix	 the	 specimens	within	 an	 hour	 of	 surgical	
removal	of	the	tumors.	Delay	in	fixation	may	cause	degradation	of	the	HRs.	A	fixation	
time	 ranging	 from	 8	 hours	 to	 72	 hours	 is	 considered	 acceptable	 by	 ASCO-CAP	
guidelines	 but	 they	 also	 caution	 about	 under-fixation,	 that	 is,	 fixation	 less	 than	 8	
hours.	 Under-fixation	 may	 contribute	 to	 insufficient	 preservation	 of	 protein	
molecules10.	 The	 analytical	 variables	 include	 the	 primary	 antibody	 clones,	 antigen	
retrieval	techniques	and	reference	standard	materials	used	for	HR	testing,	that	have	
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critical	 roles	 in	 contributing	 to	 testing	 accuracy11.	 The	 post-analytic	 phase	 involves	
interpretation	 and	 reporting	 of	 the	 test	 results	 by	 breast	 pathologists.	 The	
pathologists	use	recommended	semi-quantitative	scoring	techniques	such	as	-	Allred	
Score,	 H-Score,	 Quick	 Score	 -	 to	 evaluate	 the	HR	 test	 results.	 Although	 the	 scoring	
algorithms	 for	 all	 the	methods	 takes	 account	 of	 the	 proportion	 of	 the	 cells	 stained	
and	 the	 intensity	of	 the	 staining2,	 they	are	calculated	differently	 from	each	other11.	
Lack	 of	 quantitation	makes	 it	 difficult	 to	 standardize	 the	 post-analytic	 phase	 of	 HR	
testing.		
1.4 Scope	of	quality	assurance	in	IHC	processing			
In	 order	 to	 ascertain	 if	 a	 diagnostic	 test	 or	 assay	 is	 running	 accurately,	 it	 is	
essential	 that	 the	 test	 be	 performed	 under	 a	 robust	 Quality	 Management	 (QM)	
program2.	Every	prognostic	and	especially	predictive	biomarker	testing	by	IHC	should	
have	an	individualized	program.	An	integral	part	of	QM	is	QC,	which	includes	the	use	
of	control	materials	alongside	the	test	samples	 to	ensure	the	quality	of	 the	staining	
method.	 Clinical	 testing,	 much	 like	 scientific	 experimentation,	 requires	 parallel	
processing	 of	 material	 that	 demonstrates	 expected	 performance	 parameters	 to	
monitor	the	reliability	of	the	test,	or	experiment.	Hypothetically,	an	infinite	number	of	
controls	can	be	run	alongside	a	test,	but	practice	dictates	selecting	controls	that	cover	
the	 testing	 range	of	 the	assay.	 	Thus,	a	 standardized	assay	would	 require	uniformly	
generated	controls	to	ensure	accurate	test-to-test	performance.	But	there	are,	as	of	
now,	 no	 commercially	 available	 standardized	 reference	 materials	 for	 ER	 and	 PR	
testing.	
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Standard	 QC	 protocols	 for	 IHC	 ER	 and	 PR	 testing	 use	 positive	 and	 negative	
controls	along	with	the	test	specimens	to	minimize	discordant	findings	and	to	monitor	
antibody	and	assay	performance.	The	positive	controls	are	tissue	specimens	that	are	
positive	for	ER	and	PR	antigens	detectable	by	ER	and	PR	antibodies.	Negative	controls	
are	 tissues	 that	 lack	 ER	 and	PR	 antigens	 and	hence	 are	not	 detected	by	 ER	 and	PR	
antibodies.	 Positive	 controls	 are	 divided	 into	 two	 categories,	 external	 and	 internal	
positive	 controls.	 The	 external	 positive	 controls	 include	 archived	 breast	 tumor	
specimens	 and	 breast	 cancer	 cell	 lines	 containing	 ER	 and	 PR	 antigens.	 The	 internal	
positive	controls	are	regions	of	normal	tissue	that	express	normally	expected	levels	of	
ER	 and	 PR	 present	 within	 the	 test	 specimen.	 Positive	 reference	 controls	 monitor	
instrumentation	 error	 in	 automated	 IHC	 platforms,	 poor	 ER	 and	 PR	 antibody	
sensitivity	and	other	assay	analytic	drift,	overall	controlling	for	false	negative	results.	
Negative	 controls	 are	 also	 divided	 into	 external	 and	 internal	 controls.	 The	 internal	
negative	control	is	derived	from	the	healthy	part	of	the	patient’s	breast	and	external	
negative	 control	 is	 derived	 from	 archived	 breast	 tumors.	 Another	 type	 of	 negative	
control	 called	 negative	 reagent	 control	 monitors	 for	 non-specific	 staining	 on	 test	
specimens	by	not	applying	the	primary	antibody	to	the	test	specimen.	As	the	negative	
controls	lack	ER	and	PR	antigens,	the	objective	of	using	such	controls	is	to	monitor	for	
false	positive	staining	on	the	test	specimens12.	
1.5 Effects	of	pre-analytic	factors	on	IHC	biomarker	testing		
The	pre-analytical	phase	of	biomarker	 testing	 starts	with	 surgical	 removal	of	
tumor	 from	 patient	 until	 the	 test	 specimen	 is	 prepared	 for	 analysis13.	 Protein	
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biomarkers	 in	 tumors	 are	 labile	 to	 conditions	 like	 sudden	 temperature	 difference,	
change	in	pH,	and	metabolic	stress	conditions	during	and	after	surgery14.	A	biomarker	
portends	 prognosis	 and	 in	 some	 cases	 predicts	 the	 course	 of	 a	 disease15.	
Standardizing	pre-analytic	factors	that	influence	biomarker	expression	during	sample	
preparation	may	preserve	the	quality	of	biomarkers	and	reflect	true	biomarker	status	
after	 analysis9,13.	 The	 pre-analytic	 variables	 can	 be	 broadly	 divided	 into	 three	
categories:	surgery,	tissue	processing	and	tissue	storage.		
Briefly,	the	factors	associated	with	surgery	involve	ischemic	temperature	and	
delay	 in	fixation.	Some	of	the	variables	 in	tissue	processing	 involve	type	of	fixatives,	
duration	 of	 fixation,	 size	 of	 the	 tissue,	 and	 types	 of	 the	 tissue	 processors	 among	
others.	Some	of	the	factors	affecting	tissue	storage	are	slide	storage	temperature	and	
length	of	 storage	 time9,16.	 	Two	of	 the	pre-analytic	 factors	 that	can	be	standardized	
are	cold	ischemic	time	and	formalin	fixation	time.	
1.5.1 Ischemic	time		
Restriction	of	blood	flow	to	tissues	is	called	tissue	ischemia.	Tumors	undergo	
ischemia	 during	 surgical	 procedure	 when	 blood	 flow	 is	 restricted	 to	 the	 tissue	 by	
means	of	 clamping	blood	vessels	 to	control	bleeding.	The	 length	of	 time	 it	 takes	 to	
remove	 the	 tissue	 from	 the	 patient	 and	 place	 it	 in	 the	 preservative	 is	 known	 as	
ischemic	 time.	 Ischemic	 time	 is	 divided	 into	warm	 ischemic	 time	 and	 cold	 ischemic	
time9.	Warm	ischemic	time	is	defined	as	the	time	between	the	surgical	disruption	of	
blood	flow	to	the	tumor	until	its	removal	from	the	patient.	Cold	Ischemic	time	is	the	
duration	 between	 surgical	 removal	 of	 the	 tumor	 until	 it	 has	 been	 placed	 in	 the	
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fixative.	During	ischemic	time,	the	tumor	cells	undergo	stress	conditions	like	hypoxia,	
autolysis	and	metabolic	acidosis	that	may	degrade	the	HRs	and	other	biomarkers	of	
breast	cancer14,17.		
The	 American	 Association	 of	 Clinical	 Oncology	 –	 College	 of	 American	
Pathologists	 (ASCO-CAP)	 recommends	cold	 ischemic	 time	 less	 than	one	hour	 for	HR	
testing2.	The	recommendation	was	based	on	publications	that	studied	the	effects	of	
cold	ischemic	times	on	ER	and	PR	expression.	The	studies	were	designed	using	breast	
cancer	 specimens.	 Comparing	 paired	 needle	 core	 biopsy	 specimens	 -	 considered	 as	
control	–	that	usually	have	less	than	1	hour	delay	in	fixation,	to	excisional	specimens	
showed	that	ER	antigenicity	decreased	in	excisional	specimens	with	increase	in	delay	
in	 fixation17–19.	 The	 challenge	 has	 been	 ruling	 out	 variables	 like	 inherent	 tumor	
heterogeneity	in	clinical	specimens	that	may	contribute	to	the	decrease	in	biomarker	
antigenicity.		
1.5.2 Formalin	fixation		
As	 par	 ASCO-CAP	 guidelines	 for	 hormone	 receptor	 testing,	 breast	 cancer	
specimens	 should	 be	 immediately	 placed	 in	 10	 percent	 Neutral	 Buffered	 Formalin	
(10%	NBF)	post	surgery	and	fixed	for	minimum	of	8	hours	and	maximum	of	72	hours2.	
Formalin	 fixation	 is	 a	 chemical	 process	 that	 preserves	 proteins	 in	 tumors	 from	
undergoing	autolysis	by	cross-linking	the	lysine	residues	with	the	aldehyde	groups	of	
formalin.	Penetration	of	NBF	in	tissues	that	takes	place	at	a	rate	of	1	mm	per	hour	is	a	
relatively	faster	process	than	fixation	of	tissues.	Fixation	is	a	time	consuming	reaction	
due	 to	 the	 following	 -	 formalin	 is	 formed	when	 formaldehyde	 is	 dissolved	 in	water	
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until	 there	 is	 equilibrium	between	 aqueous	 formaldehyde	 and	methylene	 glycol.	 In	
this	reversible	reaction,	conversion	of	methylene	glycol	to	formaldehyde	is	the	rate-
limiting	 step20,21.	 In	 the	 fixation	 process,	 formaldehyde	 covalently	 links	 the	 amino	
acids	 of	 the	 adjacent	 protein	 molecules.	 Once	 the	 aldehydes	 are	 used	 up,	 more	
formaldehyde	 molecules	 are	 produced	 to	 maintain	 the	 equilibrium	 between	
formaldehyde	and	methylene	glycol22.	Given	more	time	to	the	process,	there	would	
be	sufficient	aldehyde	molecules	to	effectively	fix	the	tissue.	In	order	to	adequately	fix	
tissues,	 24	 hours	 of	 fixation	 is	 recommended23,24	 but	 for	 reliable	 ER	 IHC	 tests,	
Goldstein	(2003),	suggested	a	minimum	of	6	to	8	hours	of	fixation.	However,	a	recent	
study	 reported	 no	 difference	 in	 ER	 expression	 in	 mastectomy	 specimens	 when	
fixation	time	was	varied	from	30	minutes	to	1	week25.	Given	the	aforementioned	pre-
analytical	considerations,	a	tumor	model	with	consistent	biomarker	expression	would	
be	useful	to	design	studies	to	determine	exclusive	effects	of	cold	 ischemic	time	and	
fixation	time	on	biomarker	antigenicity.	
1.6 Study	rationale		
Derivation	of	External	Control	Material	
	
External	control	materials	for	ER	and	PR	IHC	testing	are	derived	from	archived	
breast	tumors	with	previously	reported	test	results.	Such	archived	specimens	with	a	
range	 of	 ER	 and	 PR	 expression	 levels	 are	 identified	 and	 used	 as	 external	 reference	
materials.	Although	these	controls	generally	give	satisfactory	results,	they	have	some	
limitations	 -	 archived	 breast	 cancer	 specimens	 used	 as	 controls	 have	 inherent	
heterogeneity	within	and	between	 tissues.	Moreover,	once	a	 control-tissue	block	 is	
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exhausted,	 a	 new	block	 has	 to	 be	 identified	which	will	 invariably	 have	 inconsistent	
staining	and	histological	differences	from	the	previous	control	specimens.	Hence,	due	
to	 inter	 and	 intra	heterogeneity,	 these	 controls	 are	not	necessarily	 ideal	 standards.	
Furthermore,	 the	 pre-analytic	 processing	 conditions	 of	 such	 Patient-Derived-Tumor	
(PDT)	controls	are	often	not	the	same	as	test	specimens.	The	use	of	cell	line-derived	
controls	may	 overcome	 the	 inconsistent	 staining	 reflected	 in	 PDT	 controls21	 but	 as	
they	are	grown	in	vitro,	they	are	not	histologically	representative	of	PDT	controls	and	
also	their	pre-analytic	preparation	does	not	follow	surgical	specimen	processing.		
Cell	 line-derived	 Xenografted	 (CDX)	 tumors	 generated	 in	 immunodeficient	
mice	 have	 wide	 applications	 in	 studying	 in	 vivo	 tumor	 biology	 and	 cancer	
therapeutics22.		Furthermore,	CDX	tumors	are	considered	to	be	representative	of	the	
cell	 lines	 from	which	 they	 are	 derived23.	 Unlike	 cell	 lines,	 CDX	 tumors	 show	 tumor	
morphology	 reflected	 in	 clinical	 tumor	 specimens	 and	 they	 are	 assumed	 to	 retain	
protein	expression	of	the	cell	lines	from	which	they	are	derived.	
The	purpose	of	this	thesis	is	to	demonstrate	the	possible	applications	of	well-
characterized	 breast	 cancer	 CDX	 tumors	 as	 standardized	 reference	materials	 for	 ER	
and	PR	IHC	testing	in	breast	cancer.	 In	an	effort	to	generate	standardized	controls,	 I	
asked	 the	 question:	 “How	 can	 HRs	 testing	 be	 standardized?”	 I	 hypothesized	 that	
breast	 cancer	 cell	 line-derived	 Xenografted	 tumors	 are	 representative	 of	 patient-
derived-tumors	that	can	be	used	for	QC	purposes	in	HR	IHC	testing.	
The	objectives	of	the	study	were:	
1. To	select	breast	cancer	cell	lines	with	varying	steady-state	levels	of	ER	and	PR	
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expression.	
2. To	determine	if	site	of	cell	implantation	-	mammary	fat	pad	-	had	any	effect	on	
ER	and	PR	expression	in	the	CDX	tumors.	
3. To	assess	if	the	CDX	tumors	retained	ER	and	PR	expression	of	the	cell	lines.	
4. To	 evaluate	 if	 the	 CDX	 tumors	 can	 span	 the	 range	 of	 ER	 and	 PR	 expression	
levels	of	the	PDT	controls.	
The	results	from	this	study	suggested	that	ER	and	PR	expression	levels	are	consistent	
between	 the	 cell	 lines	 and	 their	 corresponding	 CDX	 tumors.	 The	 site	 of	 cell	 line	
implantation	in	the	mice	has	no	effect	on	ER	and	PR	expression.	And	finally	the	range	
of	 ER	 and	 PR	 levels	 observed	 in	 the	 MCF7,	 T47D	 and	 MDAMB468	 CDX	 tumors	 is	
comparable	to	the	range	of	PDT	controls	routinely	used	for	testing	clinical	specimens.	
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2 Chapter	2	Materials	and	Methods	
2.1 Breast	cancer	cell	lines	
	
The	 breast	 cancer	 cell	 lines	 Hs-578Bst,	 Hs-578T,	MDAMB231,	 SKBR3,	MCF7,	
MDAMB436,	MDAMB468,	T47D,	BT474	and	MDAMB157	were	purchased	from	ATCC	
(Manassas,	 VA).	 Cell	 lines	 were	 cultured	 in	 Dulbecco’s	 Modified	 Eagle	 Medium	
(GIBCO,	Grand	 Island,	NY),	 10%	 Fetal	 Bovine	 Serum	 (GIBCO)	 and	 incubated	 at	 37°C	
with	5%	CO2.		
2.2 Cell	block	preparation		
Cell	 lines	were	resuspended	 in	3	mm	sections	of	plastic	drinking	straws	with	
1%	molten	 low	melting	point	 agarose	 at	 37°C,	 allowed	 to	 set	 at	 room	 temperature	
and	fixed	in	10	percent	Neutral	Buffered	Formalin	(10%	NBF)	for	24	hours.	Cell	blocks	
were	processed	as	routine	clinical	samples	prior	to	paraffin	embedding.		
2.3 Protein	preparation	from	cell	lines	and	cell	line-derived	Xenografted	tumors		
Protein	was	extracted	from	approximately	4.0×106	cells	for	each	cell	line	using	
the	 radioimmunoprecipitation	 (RIPA)	 cell	 lysis	 buffer.	 RIPA	 buffer	 is	 composed	 of	
sodium	dodecyl	sulfate	0.1%,	triton	X-100	1.1%,	EDTA	1.2	mM,	Tris-HCl	pH	(8.1)	16.7	
mM,	 NaCL	 16.7	 mM	 and	 1%	 protease	 inhibitor	 in	 distilled	 water.	 Protein	 was	
extracted	from	the	CDX	tumors	by	mincing	the	tumors	in	presence	of	the	RIPA	buffer	
followed	 by	 resuspending	 at	 4°C	 until	 a	 homogenized	 mixture	 was	 obtained.	 The	
homogenate	was	centrifuged	at	4°C	for	10	minutes	and	the	supernatant	was	collected	
and	stored	at	-80°C.	
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2.4 Immunoblot	analysis		
Total	protein	concentration	in	the	RIPA	buffer	extracted	from	the	cell	lines	and	
the	 CDX	 tumors	 were	 determined	 using	 the	 BioRad	 assay	 reagent	 (Berkeley,	 CA).	
Approximately	 30	 μg	 of	 each	 lysate	 was	 resolved	 in	 sodium	 dodecyl	 sulphate	
polyacrylamide	 gel	 electrophoresis	 (SDS-PAGE).	 The	 resolved	 proteins	 were	
transferred	to	the	Polyvinylidene	Fluoride	(PVDF)	membrane	(BioRad,	Berkeley,	CA).	
The	proteins	were	 immune-blotted	for	ER,	PR	and	β-actin.	ER	was	determined	using	
ER	(SP1	clone)	monoclonal	antibody	from	(Thermo	Scientific™	Lab	Vision™,	Fremont,	
CA)	and	polyclonal	ER	antibody	from	(Sigma,	St.	Louis,	MO).	PR	was	determined	using	
monoclonal	PR	antibody	(Cell	Signalling,	Boston,	MA),	and	β-actin	with	monoclonal	β-
actin	 (Sigma,	 St.	 Louis,	 MO).	 Protein	 expression	 was	 detected	 using	 enhanced	
chemiluminiscence	 (Amersham,	 Piscataway,	 NJ).	 β-actin	was	 probed	 to	 ensure	 that	
equal	quantity	of	the	test	proteins	was	loaded	in	each	well.	
2.5 Generation	of	cell	line-derived	Xenografted	tumors		
1.2X106	 cells	 were	 mixed	 with	 Cultrex®	 -	 Basement	 Membrane	 Extract	 -	
(Trevigen®	Gaithersburg,	MD)	in	a	ratio	of	1:1	(V/V)	and	injected	in	the	mammary	fat	
pads	 of	 the	 severely	 combined	 immuno-deficient	 (SCID)	 Hairless	 Outbred	 (SHO™)	
mice	from	(Charles	Rivers,	Wilmington	MA).	For	mice	injected	with	ER-positive	cells,	a	
0.72	 mg	 of	 17β-estradiol	 -	 60-day	 extended-release	 tablet	 (Innovative	 Research	 of	
America,	Sarasota,	FL)	was	inserted	using	a	10-gauge	trochar	(Innovative	Research	of	
America).	CDX	tumors	were	harvested	at	5	mm	in	longest	dimension	and	immediately	
placed	in	10%	NBF	for	24	hours	at	room	temperature	followed	by	routine	processing	
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in	 paraplast	 blocks.	 For	 every	 CDX	 tumor,	 a	 4μm	 section	 was	 stained	 with	
Hematoxylin	and	Eosin	(H&E)	to	identify	areas	of	viable	tumor.	
2.6 Tissue	microarray	construction		
Tumors	 were	 first	 assessed	 using	 4	 μm	 H&E	 sections	 for	 suitability.	 Tissue	
Microarrays	(TMAs)	were	constructed	on	an	MT-1	Arrayer	(Beecher™,	Sun	Prairie,	WI)	
using	 1	 mm	 diameter	 x	 3	 mm	 cores	 from	MCF7,	 T47D	 and	 MDAMB468	 FFPE	 cell	
blocks	 and	 tumors.	 Two	 TMAs	 were	 constructed,	 one	 of	 an	 array	 of	 6	 MCF7	 CDX	
tumors	 excised	 from	3	 different	mammary	 fat	 pad	 (MFP)	 locations	 from	 two	mice,	
and	the	other	of	CDX	tumors	from	each	of	the	three	cell	lines.	Pathologists	scored	one	
slide	of	each	TMA,	each	containing	three	cores	selected	from	each	tumor.	Cores	from	
Human	breast	 tumors	 previously	 assessed	 as	 either	 negative,	 low	 expression	 (<5%)	
and	high	expression	(>95%)	as	part	of	the	clinical	breast	service	were	used	as	controls	
and	were	placed	amongst	the	CDX	tumors	so	that	their	identity	could	not	be	revealed.	
Clearance	 for	 use	 of	 archived	 specimens	 was	 obtained	 from	 the	 regional	 Health	
Research	Ethics	authority	(HREA	13.281).	
2.7 Immunohistochemistry		
The	cell	line	microarray	and	CDX-TMAs	were	cut	into	3μ	sections	and	stained	
for	 ER	with	 ER	 (SP1)	 rabbit	monoclonal	 antibody	 (Ventana,	 Tucson,	 AZ)	 and	 for	 PR	
with	 PR	 (1E2)	 rabbit	 monoclonal	 antibody	 (Ventana,	 Tucson,	 AZ).	 The	 cell	 line	
microarray	and	CDX-TMA	sections	were	stained	in	automated	staining	platforms	that	
use	 the	 iVIEW	 DAB	 detection	 system	 and	 the	 ultraView	 DAB	 detection	 systems	
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(VentanaTM	Medical	Systems).	In	case	of	the	ultraView	system,	the	slides	underwent	
antigen	retrieval	at	95°C	for	8	minutes	in	the	Cell	Conditioner	(CC)	#1.	For	both	ER	and	
PR	 tests,	 the	 slides	 were	 incubated	 in	 pre-diluted	 primary	 antibody	 at	 36°C	 for	 4	
minutes.	The	system	uses	a	polymeric	biotin	free	detection	kit.	Following	the	primary	
antibody	incubation,	the	slides	were	treated	with	the	UV	HRP	Universal	Multimer	for	
8	minutes.	 Next	 the	 chromgen,	 UV	 3,3-diamino-benzidine	 (DAB)	 was	 added	 to	 the	
slides.	The	HRP	catalyzed	the	UV	DAB	for	8	minutes	to	stain	the	antigens	of	 interest	
brown	on	the	tissue	surface.	The	slides	were	treated	with	UV	Copper	for	4	minutes	to	
enhance	 the	 brown	 nuclear	 staining.	 Counterstaining	 was	 performed	 using	 the	
Hematoxylin	 II.	 In	 the	 iVIEW	 system,	 for	 ER	 tests,	 the	 slides	 underwent	 antigen	
retrieval	 at	 95°C	 for	 60	minutes	 in	 the	 CC	 #1.	 The	 slides	were	 incubated	with	 pre-
diluted	 primary	 antibody	 at	 37°C	 for	 8	minutes.	 For	 PR	 test,	 the	 slides	 underwent	
antigen	retrieval	at	95°C	 for	30	minutes	 in	CC	#1.	The	slides	were	 incubated	 in	pre-
diluted	primary	antibody	at	37°C	for	16	minutes.	The	iVIEW	detection	system	consists	
of	 a	 secondary	 antibody	 conjugated	 to	 biotins,	 linking	 the	 primary	 antibody	 to	 the	
StreptAvidin	 conjugated	HorseRadish	Peroxidase	 (SA-HRP).	Biotin	has	 strong	affinity	
for	streptavidin.	The	HRP	catalyzes	the	DAB	to	produce	brown	stain	at	the	site,	where	
the	proteins	are	located.	Counterstaining	was	performed	using	the	Hematoxylin	II.	
2.8 Assessment	of	the	cell	line-derived	Xenografted	tumor	microarray		
Three	 pathologists	 experienced	 in	 reporting	 breast	 biomarker	 expression,	
independently	scored	the	CDX-TMAs	(Tables	3.3a,	b,	c,	d,	e,	f	and	3.4a,	b,	c,	d,	e,	f).	
For	each	tumor	core	 in	 the	CDX-TMAs,	 the	averaged	proportion	score	was	assessed	
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for	 3	 randomly	 selected	 fields	 regardless	 of	 the	 staining	 intensity.	 An	 average	
intensity	 score	was	assigned	at	high-power	 (40X).	The	Allred	 score	 (Tables	2.8a	and	
2.8b)	was	assigned	by	summing	the	proportion	score	and	intensity	score.	
2.9 Statistical	analysis		
One-way	ANOVA	was	performed	to	determine	whether	there	was	a	significant	
difference	 in	the	ER	and	PR	expression	 levels	between	the	CDX	tumors	and	controls	
derived	from	human	breast	tumors	and	represented	with	box-and-whisker	plots	using	
GraphPad	Prism	V6	(GraphPad	Software,	La	Jolla,	CA).	A	P-value	of	<	0.05	(α	=	0.05)	
was	considered	significant.		
2.10 Microarray	imaging		
The	microarrays	were	scanned	using	a	digital	slide	scanner,	ScanScope	XT	from	
Aperio®	(Buffalo	Grove,	IL).	Images	of	the	arrays	were	taken	using	Aperio	ImageScope	
v11.2.0.780.	Representative	image	of	each	histospot	in	the	microarrays	was	saved	in	
TIFF	format.	The	figures	were	prepared	using	Adobe®	Photoshop®.	
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Table	2.10.a	Allred	Intensity	Score	
Intensity	Strength	 Intensity	Score	
Negative	 0	
Weak	 1	
Intermediate	 2	
Strong	 3	
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Table	2.10.b	Allred	Proportion	Score	
Percentage	Range	 Proportion	Score	
0	 0	
>0-1	 1	
>1-10	 2	
>10-33	 3	
>33-66	 4	
>66-100	 5	
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3 Chapter	3	Results	
3.1 Expression	of	ER	and	PR	in	breast	cancer	cell	lines	
	
In	order	to	select	cell	lines	suitable	for	evaluation	of	CDX	tumors,	the	relative	
expression	 levels	 of	 both	 ER	 and	 PR	 in	 ten	 breast	 cancer	 cell	 lines	 was	 first	
determined	using	Western	 (immuno)	blots	 (Figure	3.1a).	Of	 these,	MCF7,	T47D	and	
MDAMB468	cells	were	selected	for	further	utilization.	Agarose	cell	blocks	were	made	
from	MCF7,	T47D	and	MDAMB468	and	further	tested	for	ER	and	PR	expression	using	
IHC.	 Human	 breast	 tumors	 previously	 assessed	 as	 either	 negative,	 low	 expression	
(<5%)	and	high	expression	(>95%)	as	part	of	the	clinical	breast	service	were	used	as	
controls	to	assign	comparable	levels	of	staining	in	the	cell	blocks.	MCF7	cells	displayed	
strong	 nuclear	 staining	 of	 both	 ER	 and	 PR	while	 T47D	 cells	 showed	 relatively	weak	
nuclear	ER	and	strong	nuclear	PR	staining.	Staining	for	both	ER	and	PR	was	negative	in	
MDAMB468	cells	(Figure	3.1.b).	
	
	
	
	 19	
	
Figure	3.1.a	Immunoblot	analyses	of	ER	and	PR	expression	in	breast	
cancer	cell	lines	Steady-state	levels	of	ER	and	PR	expression	were	assayed	
by	immuno-blot.	β-actin	was	used	as	loading	control.		
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Figure	3.1.b	IHC	analyses	of	ER	and	PR	expression	in	breast	cancer	cell	lines	
MCF7,	T47D	and	MDAMB468	cell	lines	analysed	by	IHC	using	controls	derived	from	human	
tumors	with	varying	ER	and	PR	staining	intensity.	Images	were	taken	at	(10X).	
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3.2 ultraView	DAB	detection	system	has	superior	signal	to	noise	ratio	over	the	
iVIEW	DAB	detection	system	
	
In	 the	 IHC	 laboratory	 at	 Eastern	Health,	NL,	 estrogen	 receptor	 IHC	 tests	 are	
performed	using	BenchMark	 XTTM	and	 and	BenchMark	ULTRATM	automated	 staining	
systems	 that	 use	 iVIEW	 DAB	 (avidin-biotin	 based)	 and	 ultraViewTM	 Universal	 DAB	
(polymer	based)	detection	kits	respectively.	In	order	to	determine	the	performance	of	
the	detection	 systems	on	 the	CDX	 tumors,	we	 stained	MCF7	CDX	 tumors	 alongside	
previously	 assessed	 human	 breast	 tumors	 (HBT)	 as	 controls	 for	 ER	 expression.	 The	
ultraView	 detection	 system	 showed	 relatively	 better	 signal	 to	 noise	 ratio	 than	 the	
iVIEW	system	in	the	MCF7	CDX	tumors,	notably	observed	in	the	negative	ER	control	
panels.	 Both	 iVIEW	 and	 ultraView	 produced	 relatively	 less	 non-specific	 background	
noise	in	the	HBT	controls.	These	observations	suggested	that	the	ultraView	detection	
system	produces	superior	signal	to	noise	ratio	in	the	CDX	tumors	in	comparison	to	the	
iVIEW	detection	system.	
	
	
	
	
	
	
	
	
	
	
	
	 22	
	
	
Figure	3.2	Comparison	of	detection	systems	on	staining	performance	
Images	 1	 and	 2	 are	 of	MCF7	 CDX	 tumor	 and	 image	 4	 and	 5	 are	 of	 human	 breast	
tumors	(HBT)	stained	with	the	 iVIEW	detection	system	with	corresponding	 images	3	
and	 6	 stained	 with	 Hematoxylin	 &	 Eosin	 (H&E).	 Images	 7	 and	 8	 are	 of	MCF7	 CDX	
tumors	and	image	10	and	11	are	of	HBTs	stained	with	the	ultraView	detection	system	
and	H&E	on	9	and	12.	Images	were	taken	at	(40X).	
	
	
	
	
	
	
	
	
	
	
	
	 23	
3.3 CDX	tumors	consistently	maintain	ER	and	PR	expression	levels	irrespective	of	
implantation	sites		
To	 construct	 CDX	 tumors,	 cell	 lines	 cultured	 in	 vitro	were	 implanted	 in	 the	
mammary	 fat	 pads	 of	 recipient	 immunodeficient	 mice	 as	 described.	 In	 order	 to	
determine	 if	 the	 placement	 of	 the	 seeded	 cell	 lines	 had	 an	 effect	 on	 biomarker	
expression,	 CDX	 tumors	 were	 grown	 in	 different	 fat	 pad	 locations	 and	 in	 different	
mice	and	compared	for	ER	and	PR	expression.		
	 Six	MCF7	CDX	 tumors	were	assessed	 from	two	mice	 from	mammary	 fat	pad	
(MFP)	site	4,	5,	and	10	as	shown	in	(Figure	3.3.a).	The	expression	of	ER	in	MCF7	CDX	
tumors	 and	 human	 breast	 tumors	 (HBT)	 that	 are	 used	 as	 controls	 under	 standard	
operating	protocols	for	biomarker	testing,	was	assessed	by	three	pathologists.	The	ER	
Allred	 score	 ranged	 between	 7-8	 and	 was	 consistent	 in	 the	 MCF7	 CDX	 tumors	
regardless	of	the	site	of	implantation	and	into	which	mice	the	tumors	were	produced.	
The	 three	HBT	 controls	were	 reported	 as	 strong,	 intermediate	 and	 negative	 for	 ER	
expression.	ER	expression	 in	 the	MCF7	CDX	tumors	was	concordant	with	 the	strong	
ER	control	shown	in	(Figure	3.3.b&c).	Similarly,	PR	expression	among	the	6	MCF7	CDX	
tumors	 ranged	between	6-8	 (Figure	 3.3d&e).	 	 These	 observations	 suggest	 that	 CDX	
tumors	can	be	grown	consistently	and	are	comparable	to	patient	derived	controls.	
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Figure	3.3.a	Mammary	fat	pad	site	numbers	and	the	mouse	numbers	from	where	
MCF7	CDX	tumors	were	harvested	
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Figure	3.3.b	Average	Allred	ER	scores	of	the	MCF7	CDX	tumors	
													Box-and-whisker	plot	is	used	to	represent	the	average	Allred	ER	scores	of	the	
MCF7	 CDX	 tumors	 (represented	 with	 the	 host	 and	MFP	 site	 numbers)	 and	
three	control	human	breast	tumors.	For	each	box,	the	middle	line	represents	
the	median	score,	 the	 lower	whisker	 represents	 lowest	score	and	the	upper	
whisker	represents	the	highest	score.	Non	Detectable	(ND).	
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Figure	3.3.c	ER	Staining	of	MCF7	CDX	Tumors	
																Representative	IHC	staining	corresponding	to	part	b.	Images	were	taken		
																at	(10X).		
	
	
	
	
	
	
	
	
	
	 27	
	
	
Figure	3.3.d	Average	Allred	PR	Score	of	MCF7	CDX	Tumors	
													Box	and	whisker	plot	is	used	to	represent	the	average	Allred	PR	scores	
of	 the	 MCF7	 CDX	 tumors	 (represented	 with	 the	 host	 and	 MFP	 site	
numbers)	and	 three	control	human	breast	 tumors.	 For	each	box,	 the	
middle	line	represents	the	median	score,	the	lower	whisker	represents	
lowest	score	and	the	upper	whisker	represents	the	highest	score.	Non	
Detectable	(ND).	
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Figure	3.3.e	PR	Staining	of	MCF7	CDX	Tumors	
								Representative	IHC	staining	corresponding	to	part	d.	Images	were	taken	at	(10X).		
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Table	3.3.a	ER	Average	Proportion	Score	(APS)	–	MCF7	CDX	Tumors	
Assessment	of	 ER	expression	by	 three	pathologists	 in	 6	MCF7	CDX	 tumors	denoted	
with	Mouse/Site	 (M/S)	 numbers	 and	 three	 human	 breast	 tumor	 controls	 using	 the	
Proportion	Score	(PS)	on	three	randomly	selected	fields	(F).	The	PS	of	all	three	fields	
was	averaged	to	obtain	the	Average	Proportion	Score	(APS)	for	each	tumor.	
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Table	3.3.b	ER	Intensity	Score	-	MCF7	CDX	Tumors	
Assessment	of	ER	expression	by	 three	pathologists	 in	6	MCF7	CDX	tumors	denoted	with	
Mouse/Site	 (M/S)	 numbers	 and	 three	 human	 breast	 tumor	 controls	 using	 the	 Intensity	
Score	(IS).	
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Table	3.3.c	ER	Allred	Score	-	MCF7	CDX	Tumors	
Assessment	of	ER	expression	by	three	pathologists	in	6	MCF7	CDX	tumors	denoted	with	
Mouse/Site	 (M/S)	 numbers	 and	 three	 human	 breast	 tumor	 controls	 using	 the	 Allred	
Score	(AS).	
		
	 32	
	
Table	3.3.d	PR	Average	Proportion	Score	(APS)	–	MCF7	CDX	Tumors	
Assessment	of	PR	expression	by	 three	pathologists	 in	6	MCF7	CDX	tumors	denoted	with	
Mouse/Site	(M/S)	numbers	and	three	human	breast	tumor	controls	using	the	Proportion	
Score	(PS)	on	three	randomly	selected	fields	(F).	The	PS	of	all	three	fields	was	averaged	to	
obtain	the	Average	Proportion	Score	(APS)	for	each	tumor.	
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Table	3.3.e	PR	Intensity	Score	–	MCF7	CDX	Tumors	
Assessment	of	PR	expression	by	 three	pathologists	 in	6	MCF7	CDX	tumors	denoted	with	
Mouse/Site	 (M/S)	 numbers	 and	 three	 human	 breast	 tumor	 controls	 using	 the	 Intensity	
Score	(IS).	
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Table	3.3.f	PR	Allred	Score	–	MCF7	CDX	Tumors	
Assessment	of	PR	expression	by	 three	pathologists	 in	6	MCF7	CDX	tumors	denoted	with	
Mouse/Site	(M/S)	numbers	and	three	human	breast	tumor	controls	using	the	Allred	Score	
(AS).	
	
	
	
	 35	
3.4 Determination	of	ER	and	PR	expression	in	Xenografted	tumors	derived	from	
different	cell	lines	
	
Each	of	the	three	cell	lines	consistently	demonstrated	their	expected	levels	of	
biomarker	 expression,	whether	 grown	 in	 vitro	or	 as	 CDX	 tumors,	 as	 determined	 by	
immunoblot	(Figure	3a).		To	assess	whether	the	CDX	tumors	were	comparable	to	the	
range	 of	 controls	 used	 for	 biomarker	 testing,	 pathologists	 blind-scored	 a	 tumor	
microarray	 of	 a	 series	 of	 cores	 that	 consisted	 of	 CDX	 tumors	 and	 one	 control	 each	
representing	a	negative,	an	intermediate	and	strong	expresser	of	ER.		
As	can	be	seen	in	figure	3c,	ER	expression	was	undetectable	in	the	CDX	tumors	
derived	from	the	MDAMB468	cell	line,	which	were	consistently	scored	for	ER	as	most	
similar	(p<0.05)	to	the	negative	tumor	control.	Similarly,	CDX	tumors	derived	from	the	
most	 strongly	 expressing	 MCF7	 cell	 line	 were	 most	 similar	 (p<0.05)	 to	 the	 strong	
tumor	 control.	 Likewise,	 T47D	 CDX	 tumors	 were	 most	 similar	 to	 the	 intermediate	
tumor	control.	
Both	 the	 MCF7	 and	 T47D	 cell	 line	 derived	 CDX	 tumors,	 which	 showed	 the	
highest	 levels	 of	 PR	 expression	 were	 most	 similar	 to	 the	 strongly	 PR-expressing	
control	 (P<0.05).	 The	MDAMB468	 CDX	 tumor,	 for	which	 PR	was	 undetectable,	was	
also	most	similar	to	the	negative	PR	expressing	control.	These	observations	suggested	
that	 CDX	 tumors	 are	 indistinguishable	 from	 archived	 specimens	 used	 for	 testing	
controls.		
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Figure	3.4.a	Average	Allred	ER	Score	of	CDX	Tumors	Generated	from	Different	Cell	Lines	
			Box-and-whisker	plot	is	used	to	represent	the	average	Allred	ER	scores	of	MCF7,	T47D	and	
MDAMB468	 CDX	 tumors	 and	 three	 human	 breast	 tumors	 controls.	 For	 each	 box,	 the	
middle	 line	 represents	 the	 median	 score,	 the	 lower	 whisker	 represents	 lowest	
score	 and	 the	 upper	 whisker	 represents	 the	 highest	 score.	 	 P<0.05	 compared	 to	
strong	ER	control.	**P<0.05	compared	to	intermediate	ER	control.	Non	Detectable	(ND).	
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Figure	3.4.b	ER	Staining	of	CDX	Tumors	Generated	from	Different	Cell	Lines	
			Representative	IHC	images	corresponding	to	part	(a).	The	IHC	images	were	taken	at	(10X).		
	 38	
	
Figure	3.4.c	Immunoblot	analyses	of	ER	expression	in	CDX	tumors	
									ER	expression	levels	in	MCF7,	T47D	and	MDAMB468	CDX	tumors	determined	by										
immunoblot.	Β-actin	used	as	loading	control.	
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Figure	3.4.d	Average	Allred	PR	Score	of	CDX	Tumors	Generated	from	Different	Cell	Lines	
Box-and-whisker	plot	is	used	to	represent	the	average	Allred	PR	scores	of	MCF7,	T47D	and	
MDAMB468	 CDX	 tumors	 and	 three	 human	 breast	 tumors	 controls.	 For	 each	 box,	 the	
middle	 line	 represents	 the	 median	 score,	 the	 lower	 whisker	 represents	 lowest	
score	 and	 the	 upper	 whisker	 represents	 the	 highest	 score.	 *P<0.05	 compared	 to	
intermediate	ER	control.	Non	Detectable	(ND).	
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Figure	3.4.e	PR	Staining	of	CDX	Tumors	Generated	from	Different	Cell	Lines	
Representative	IHC	images	corresponding	to	part	(d).	The	IHC	images	were	taken	at	(10X).		
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Table	3.4.a	ER	Proportion	Score	-	CDX	Tumors	
Assessment	of	ER	expression	by	three	pathologists	in	three	biological	replicates		
of	each	CDX	tumor	type	and	three	human	breast	tumor	controls	using	the		
Proportion	Score	(PS)	on	three	randomly	selected	fields	(F).	The	PS	of	all	three		
fields	was	averaged	to	obtain	the	Average	Proportion	Score	(APS)	for	each	tumor.	
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Table	3.4.b	ER	Intensity	Score	-	CDX	Tumors	
Assessment	of	ER	expression	by	three	pathologists	in	three	biological	replicates	
of	each	CDX	tumor	type	and	three	human	breast	tumor	controls	using	the	
Intensity	Score	(IS).	
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Table	3.4.c	ER	Allred	Score	-	CDX	Tumor	
Assessment	of	ER	expression	by	three	pathologists	in	three	biological	replicates	
of	each	CDX	tumor	type	and	three	human	breast	tumor	controls	using	the	Allred	
Score	(AS).	
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Table	3.4.d	PR	Proportion	Score	-	CDX	Tumors	
Assessment	 of	 PR	 expression	 by	 three	 pathologists	 in	 three	 biological	
replicates	 of	 each	 CDX	 tumor	 type	 and	 three	 human	breast	 tumor	 controls	
using	the	Proportion	Score	(PS)	on	three	randomly	selected	fields	(F).	The	PS	
of	all	three	fields	was	averaged	to	obtain	the	Average	Proportion	Score	(APS)	
for	each	tumor.	
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Table	3.4.e	PR	Intensity	Score	-	CDX	Tumors	
Assessment	of	PR	expression	by	three	pathologists	in	three	biological	replicates	of	
each	CDX	tumor	type	and	three	human	breast	tumor	controls	using	the	Intensity	
Score	(IS).	
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Table	3.4.f	PR	Allred	Score	-	CDX	Tumor	
Assessment	of	PR	expression	by	three	pathologists	in	three	biological	replicates	of	
each	CDX	tumor	type	and	three	human	breast	tumor	controls	using	the	Allred	Score	
(AS).	
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4 Chapter	4	Discussion	
4.1 Development	of	reproducible	controls	for	ER	and	PR	IHC	testing	
	
Accurate	predictive	breast	 cancer	biomarker	analysis	by	 IHC	 is	paramount	 in	
determining	the	correct	treatment	for	the	patients	and	also	in	deciding	if	the	patients	
can	be	spared	of	 the	adverse	consequences	of	 ineffective	 treatment	of	 the	disease.	
Testing	accuracy	 is	contingent	on	the	application	of	stringent	QC	on	every	aspect	of	
the	 IHC	 assay2,11.	 Standardized	 reference	materials	 are	 the	 core	 components	 of	QC	
that	can	ensure	the	biomarker	testing	reliability.		
In	 an	 effort	 to	 standardize	 breast	 cancer	 biomarker	 testing	 by	 IHC,	 we	
hypothesized	 breast	 CDX	 tumors	 are	 representative	 of	 patient-derived-tumor	 (PDT)	
controls	 and	 that	 they	 can	 be	 used	 for	 the	 QC	 purposes.	 In	 this	 study	 my	 data	
suggested	 that	 the	 CDX	 tumors	 are	 representative	 of	 the	 PDT	 and	 that	 they	 are	
consistent	in	expressing	the	breast	cancer	biomarkers.	This	feature	of	the	CDX	tumors	
potentiates	their	application	as	standardized	QC	materials	for	IHC	ER	and	PR	testing.	
We	have	specifically	focused	on	the	ER	and	PR	expression	 in	the	CDX	tumors	 in	this	
study.	
4.2 The	benefits	of	CDX	tumors	as	controls	over	PDT	and	cell	line-derived	controls		
	
Archived	breast	tumors	with	known	varying	range	of	the	ER	and	PR	expression	
are	used	as	 external	 quality	 control	materials	 alongside	 the	 test	 specimens.	 The	ER	
and	PR	 levels	 in	 the	PDT	 controls	 should	 range	 from	strong	 to	negative	expression.	
This	range	of	expression	in	the	PDT	controls	makes	them	graded	calibrators	of	ER	and	
PR	 IHC	 testing12.	 However,	 the	 PDTs	 used	 as	 external	 controls	 are	 not	 the	 ideal	
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reference	 standards	 because	 the	 ER	 and	 PR	 expression	 in	 such	 controls	 is	 not	
reproducible	due	to	the	invariable	differences	in	tumors	from	different	patients	or	the	
inherent	 heterogeneity	 that	 exist	 within	 the	 tumors26.	 For	 instance,	 when	 an	
intermediate	 or	weak	 graded	 ER	 expressing	 control	 is	 exhausted,	 the	 technologists	
has	 to	 select	 another	 control	 from	 the	archive	and	validate	 the	new	control	before	
running	 it	 for	 clinical	 specimen	 testing.	 Although	 the	 newly	 selected	 control	 may	
provide	 satisfactory	 staining	 performance,	 the	 biomarker	 expression	 level	 may	 be	
slightly	different	from	the	previous	control.	This	subtle	difference	in	staining	between	
the	new	and	 the	previous	 controls	may	be	difficult	 to	 determine	using	pathologist-
based	 semi-quantitative	 assessment.	 Also	 such	 PDT	 controls	may	 have	 pre-analytic	
processing	different	 from	the	 test	 specimens.	 Lastly,	 such	practice	of	using	 the	PDT	
controls	destroys	the	archive	tissue	blocks.		
The	 breast	 cancer	 cell	 line-derived	 controls	 have	 long	 been	 proposed	 as	 a	
reliable,	 relatively	 accurate,	 and	 abundant	 control	materials	 that	 can	 gauge	 the	 ER	
and	 PR	 assay	 sensitivity	 due	 to	 their	 consistent	 biomarker	 expression27,26.	 MCF7	
breast	cancer	cells	have	been	used	as	the	core	component	of	“the	Quicgel	Method”.	
As	 a	 matter	 of	 fact,	 this	 technique	 was	 used	 as	 one	 of	 the	 initial	 attempts	 to	
quantitatively	measure	 the	ER	expression	 in	 invasive	breast	cancer	 specimen	 tested	
by	IHC28.	However,	the	cell	 line-derived	controls	may	not	account	for	the	changes	in	
biomarker	 expression	 as	 a	 result	 of	 the	 pre-analytic	 variables	 as	 they	 are	 not	
histologically	 representative	 of	 the	 PDT	 controls.	 Pre-analytic	 tissue	 processing	 is	 a	
major	area	of	concern	in	quality	assurance	of	the	HR	IHC	testing11.	Ideally	the	control	
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materials	 should	 have	 the	 same	 pre-analytic	 processing	 as	 the	 test	 specimens,	 to	
monitor	changes	 in	antigenicity	 in	 the	 test	 specimens	as	a	 result	of	 the	pre-analytic	
variables.		
In	this	study,	controls	were	generated	with	consistent	ER	and	PR	expression	as	
found	in	the	cell	 lines	but	at	the	same	time	have	the	histology	similar	to	that	of	the	
PDT	controls.	I	generated	breast	cancer	CDX	tumors	and	determined	their	ER	and	PR	
expression	 levels	 in	 relation	 to	 human	 breast	 tumors	 with	 known	 ER	 and	 PR	
expression.		
In	an	attempt	to	recapitulate	the	range	of	the	ER	and	PR	expression	of	the	PDT	
controls	in	the	CDX	tumors,	I	selected	three	breast	cancer	cell	lines	with	steady-state	
varying	levels	of	ER	and	PR	expression.	The	MCF7	cell	lines	strongly	expressed	ER	and	
PR,	 the	T47D	showed	 intermediate	ER	expression	but	 strong	PR	expression	and	 the	
MDAMB468	expressed	neither	 ER	nor	PR.	 In	order	 to	determine	 if	 CDX	 tumors	 can	
represent	the	PDTs,	we	orthotopically	injected	the	MCF7	cells	in	various	MFP	sites	in	
the	immunodeficeint	mice.	The	MCF7	CDX	tumors	showed	consistently	strong	ER	and	
PR	 expression	 regardless	 of	 the	 sites	 of	 cell	 implantation	 or	 the	 host.	 The	
characteristic	 strong	 ER	 and	 PR	 expression	 of	 MCF7	 cell	 line	 was	 reflected	 in	 the	
corresponding	CDX	 tumors.	The	 strong	ER	expression	of	 the	MCF7	CDX	 tumors	was	
comparable	 with	 the	 strong	 ER	 Human	 Breast	 Tumor	 (HBT)	 control.	 These	
observations	suggest	that	ER	and	PR	expression	can	be	reproduced	in	the	CDX	tumors	
harvested	from	different	MFP	sites	in	the	mice.	In	order	to	develop	a	control	system	
that	 provides	 a	 range	 of	 ER	 and	 PR	 expression	 presented	 by	 the	 PDT	 controls,	 I	
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implanted	 the	mice	with	MCF7,	T47D	and	MDAMB468	cells.	 The	MCF7	CDX	 tumors	
showed	 ER	 and	 PR	 expression	 comparable	 to	 the	 strong	 ER	 control.	 The	 T47D	CDX	
tumors	 showed	 ER	 expression	 comparable	 to	 the	 intermediate	 ER	 control	 but	 PR	
expression	 comparable	 to	 the	 strong	 ER	 control	 and	 the	 MDAMB468	 CDX	 tumors	
showed	ER	and	PR	expression	comparable	to	the	negative	ER	and	PR	control.	These	
results	suggested	that	staining	patterns	of	the	CDX	tumors	were	consistent	with	cell	
lines	 from	 which	 they	 were	 derived	 and	 they	 also	 cover	 the	 range	 of	 ER	 and	 PR	
expressions	of	the	PDT	controls.	
4.3 The	use	of	tissue	microarray	to	evaluate	ER	and	PR	antigen	heterogeneity	in	
the	CDX	tumors	
	
The	TMA	has	been	employed	as	one	of	 the	QC	tools	 for	 routine	 IHC	tests	 to	
improve	 IHC	 staining	 performance29.	 The	 TMA	 approach	 was	 recently	 used	 to	
standardize	ER	tests.	The	concept	is	to	consolidate	multiple	tissue	cores	with	varying	
biomarker	 expression	 in	 an	 array	 to	 monitor	 the	 assay	 sensitivity	 and	 hence	 to	
calibrate	the	biomarker	expression	 levels4.	But	such	controls	may	not	be	considered	
standardized	as	tissues	in	the	TMA	block	may	have	indefinite	pre-analytical	processing	
conditions.	Tumor	heterogeneity	is	another	factor	that	confounds	the	functionality	of	
such	control	system,	as	the	tumor	cores	selected	to	construct	the	microarray	may	not	
represent	the	protein	expression	profile	of	the	whole	tumors.		
Nevertheless,	the	TMA	control	methodology	can	be	very	useful	 if	the	tumors	
constituting	 the	 microarray	 have	 undergone	 pre-analytic	 processing	 recommended	
standard	 for	 the	biomarker	 testing.	This	will	ensure	relatively	better	 rescuing	of	 the	
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antigen	of	 interest.	 In	this	study,	 I	constructed	TMAs	with	the	CDX	tumors.	The	CDX	
tumors	after	excision	were	immediately	placed	in	the	fixative	and	fixed	for	24	hours.	
These	 pre-analytic	 conditions	 followed	 are	 the	 standard	 protocol	 recommended	 by	
ASCO-CAP	guidelines	for	ER	and	PR	testing.	The	cores	were	withdrawn	from	random	
regions	 of	 CDX	 tumor	 blocks	 to	 construct	 the	 microarray.	 I	 found	 that	 ER	 and	 PR	
expression	 was	 consistently	 and	 reproducibly	 high	 in	 the	 MCF7	 CDX	 tumor	 cores,	
consistently	 and	 reproducibly	 high	 PR	 but	 intermediate	 ER	 expression	 in	 the	 T47D	
CDX	tumor	cores	and	no	ER	and	PR	expression	in	the	MDAMB468	CDX	tumor	cores	in	
the	 TMA.	 This	 suggested	 that	 ER	 and	 PR	 antigens	 were	 consistently	 and	 uniformly	
distributed	in	the	CDX	tumors.	
4.4 The	applications	of	CDX	tumors	
	
The	 effect	 of	 pre-analytic	 variables	 such	 as	 cold	 ischemic	 time	 (time	 to	
fixation),	duration	of	fixation,	tissue	processing	is	difficult	to	study	prospectively	with	
clinical	 specimens	 due	 to	 tumor	 heterogeneity	 and	 scarce	 tissue	 availability.	 The	
inherently	 inconsistent	 biomarker	 expression	of	 the	 tumors	makes	 them	unsuitable	
subjects	 to	 study	 the	 effects	 of	 pre-analytic	 variables30.	 On	 the	 other	 hand,	 the	
consistent	ER	and	PR	expression	of	the	CDX	tumors	and	their	histologic	similarity	to	
the	clinical	specimens	make	them	useful	subjects	to	perform	prospective	studies	on	
ER	and	PR	expression	as	a	function	of	the	pre-analytic	variables.		
Besides	 their	 possible	 application	 in	 studying	 pre-analytic	 variables,	 the	 CDX	
tumors	can	be	used	to	study	or	validate	sensitivity	and	specificity	of	new	antibodies,	
detect	assay	analytic	drifts	as	result	of	reagents	or	instrumentation	errors.	One	of	the	
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biggest	challenges	in	the	ER	and	PR	IHC	testing	has	been	the	quantitation	of	protein	
expression.	The	lack	of	quantitation	makes	it	difficult	to	standardize	reporting	of	the	
test	 results.	 Currently	 pathologists	 use	 scoring	methods	 that	 give	 semi-quantitative	
values	 to	 the	 ER	 and	 PR	 expression	 to	 report	 the	 test	 results.	 Automated	 image	
analysis	over	two	decades	has	shown	considerable	advancement	in	quantifying	the	ER	
and	PR	expression	in	the	test	specimens31–33.	In	our	study,	ER	and	PR	expression	in	the	
CDX	 tumors	was	evaluated	using	one	of	 the	 conventional	pathologist-based	 scoring	
methods,	the	Allred	score.	The	consistency	in	scoring	among	the	three	scorers	makes	
the	 CDX	 tumors	 an	 ideal	 platform	 to	 validate	 the	 automated	 image	 analysis	
techniques	with	the	conventional	pathologist-based	scoring	techniques.		
4.5 Weaknesses	and	merits	of	the	CDX	tumor	approach		
	
	When	stained	using	 the	 iVIEW	detection	system,	MCF7	CDX	tumors	showed	
significantly	noisier	background	compared	to	the	routine	control	specimens.	But	the	
non-specific	background	was	remarkably	improved	when	the	MCF7	CDX	tumors	were	
stained	using	ultraView	 (UV)	detection	kit	 (Figure	3.2a).	The	 iVIEW	 system	 is	avidin-
biotin	based	unlike	UV,	which	 is	polymer	based.	A	major	problem	with	avidin-biotin	
system	 is	 that,	 if	 the	 specimen	 to	 be	 tested	 is	 rich	 in	 endogenous	 biotins	 then	
streptavidin	would	bind	to	them	and	produce	the	unwanted	background	noise.	It	may	
be	 possible	 that	 in	 the	 CDX	 tumors,	 the	mouse	 stromal	 cells	 are	 rich	 in	 biotin	 that	
produces	 the	 high	 noise	 to	 signal	 ratio.	 On	 the	 contrary,	 the	 UV	 system	 uses	 a	
polymer	 backbone	 conjugated	 with	 secondary	 antibodies	 and	 multiple	 HRP	
molecules.	 The	 absence	 of	 streptavidin	 ensures	 no	 non-specific	 avidin-biotin	
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interaction.	Such	properties	of	the	UV	systems	produces	superior	signal	to	noise	ratio	
compared	to	the	iVIEW	system34.	
Generating	 CDX	 tumors	 is	 an	 expensive	 procedure	 and	 it	 requires	 technical	
expertise.	 If	 an	 IHC	 laboratory	 is	 interested	 to	 make	 in-house	 CDX	 tumors	 for	 QC	
purposes,	it	requires	tissue	culture	and	animal	care	facilities.	Provided	the	availability	
of	tissue	culture	facility,	it	is	essential	that	the	batch	number	of	the	cell	lines	used	to	
generate	the	CDX	tumors	be	documented	because	it	has	been	reported	that	there	are	
subtle	 changes	 in	 protein	 expression	 between	 different	 batches	 of	 the	 same	 cell	
lines26.	 It	 is	 possible	 that	 ER	 and	 PR	 expression	 level	 in	 the	 CDX	 tumors	may	 show	
variation	from	expected	staining	intensity	if	undocumented	cell	lines	are	used.	Hence	
regular	validation	of	the	cell	lines	is	imperative.	
Despite	 such	 limitations,	 there	 are	 substantial	 benefits	 of	 the	 implication	 of	
the	CDX	 tumors	 for	 standardizing	not	only	breast	 cancer	biomarker	 testing	but	also	
other	 cancer	 biomarker	 testing.	 Multiple	 CDX	 tumors	 can	 be	 generated	 from	 one	
mouse	-	one	mouse	can	generate	5	to	6	CDX	tumors	depending	on	the	number	of	cell	
implantation	 MFP-sites.	 	 Furthermore,	 for	 the	 QC	 purposes,	 CDX-TMA	 can	 be	
constructed	 with	 only	 0.5	 to	 1	mm	 core	 of	 CDX	 tumors.	 So	 one	 batch	 of	 the	 CDX	
tumors	 from	 one	mouse	 can	 provide	 sufficient	 control	materials	 that	 will	 last	 long	
enough	to	perform	multiple	tests.	
4.6 Conclusion	
	
In	 this	 study,	 I	 demonstrated	 a	 method	 of	 generating	 standardized	 control	
materials	 for	ER	and	PR	 IHC	testing.	We	showed	CDX	tumors	are	comparable	to	the	
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gold	 standard	 -	 PDT	 controls.	 We	 used	 semi-quantitative	 values	 of	 ER	 and	 PR	
expression	 to	 characterize	 each	 of	 the	 three	 CDX	 tumors;	 MCF7,	 T47D	 and	
MDAMB468.	But	in	order	to	determine	the	near-exact	quantity	of	proteins	expressed	
in	 CDX	 tumors,	 the	 tumor	 sections	 should	 be	 assessed	 using	 automated	 image	
analysis	 techniques.	 As	 IHC	 has	 been	 increasingly	 used	 as	 a	 therapy	 decisive	
technique,	 it	 is	essential	that	biomarker	expression	in	test	specimens	be	reported	in	
exact	quantity.	This	would	require	the	biomarker	expression	in	the	control	materials	
to	 be	 reported	 with	 quantitative	 values	 as	 well.	 If	 the	 CDX	 tumors	 are	 used	 as	
reference	materials	 alongside	 the	 test	 specimens	and	 the	 staining	 is	 assessed	using	
automated	image	analysis,	the	exact	values	of	controls	and	test	specimens	would	not	
only	assist	the	pathologists	but	the	clinicians	in	deciding	the	appropriate	therapy	for	
the	patients.	
4.7 Future	directions	
	
The	 consistent	 expression	 of	 proteins	 in	 the	 CDX	 tumors	makes	 them	 ideal	
tissues	 to	 study	 the	 effects	 of	 pre-analytic	 variables	 on	 biomarker	 expression.	 For	
example,	CDX	tumours	can	be	exposed	to	defined	cold	ischemic	time	ranging	from	0	
hours	 to	24	hours	and	defined	 fixation	 times	 ranging	 from	1	hour	 to	120	hours.	As	
stable	fixation	is	achieved	at	around	24	hours10,35,	 it	will	be	possible	to	compare	the	
biomarker	expression	status	of	these	different	time	points	with	the	stable	pre-analytic	
conditions	-	CIT	of	0	hours	and	fixation	time	of	24	hours	-	to	suggest	a	time	range	for	
cold	ischemia	and	fixation	for	the	clinical	specimens.		
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